Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus - PubMed (original) (raw)
Case Reports
. 2019 Oct;19(10):2944-2948.
doi: 10.1111/ajt.15398. Epub 2019 May 21.
Affiliations
- PMID: 31012522
- DOI: 10.1111/ajt.15398
Free article
Case Reports
Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus
Abbie D Leino et al. Am J Transplant. 2019 Oct.
Free article
Abstract
Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U.S. Food and Drug Administration (FDA) in June 2018 as an adjuvant treatment for refractory epilepsy (Epidiolex; GW Pharmaceuticals). CBD is metabolized by cytochrome P450 (CYP)3A4 and CYP2C19 with a growing body of evidence suggesting it is also a potent inhibitor of these pathways. We report for the first time a significant drug-drug interaction between the purified CBD product and tacrolimus. A participant in a CBD clinical trial for epilepsy who was also receiving tacrolimus showed an approximately 3-fold increase in dose-normalized tacrolimus concentrations while receiving 2000-2900 mg/day of CBD. Our report delineates an important concern for the transplant community with the increasing legalization of cannabis and advent of an FDA-approved CBD product. Larger studies are needed to better understand the impact of this drug-drug interaction in solid organ transplant recipients.
Keywords: alternative and complementary medicine; clinical research/practice; drug interaction; immunosuppressant - calcineurin inhibitor: tacrolimus; immunosuppression/immune modulation; pharmacology.
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
Similar articles
- Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE, Szaflarski JP. Gaston TE, et al. Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y. Curr Neurol Neurosci Rep. 2018. PMID: 30194563 Review. - Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.
Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Geffrey AL, et al. Epilepsia. 2015 Aug;56(8):1246-51. doi: 10.1111/epi.13060. Epub 2015 Jun 26. Epilepsia. 2015. PMID: 26114620 - Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Patsalos PN, Szaflarski JP, Gidal B, VanLandingham K, Critchley D, Morrison G. Patsalos PN, et al. Epilepsia. 2020 Sep;61(9):1854-1868. doi: 10.1111/epi.16674. Epub 2020 Sep 12. Epilepsia. 2020. PMID: 32918835 Free PMC article. Review. - Cannabinoid therapy in epilepsy.
Billakota S, Devinsky O, Marsh E. Billakota S, et al. Curr Opin Neurol. 2019 Apr;32(2):220-226. doi: 10.1097/WCO.0000000000000660. Curr Opin Neurol. 2019. PMID: 30676535 Review. - Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
Golub V, Reddy DS. Golub V, et al. Adv Exp Med Biol. 2021;1264:93-110. doi: 10.1007/978-3-030-57369-0_7. Adv Exp Med Biol. 2021. PMID: 33332006 Review.
Cited by
- Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug-Drug Interactions Between Immunosuppressants and Cannabis-Derived Products.
Allen MR, Wightman GP, Zhu Z, Poliak A, Smith DM, Dredze M, Ayers JW. Allen MR, et al. Drug Saf. 2024 Sep 18. doi: 10.1007/s40264-024-01481-x. Online ahead of print. Drug Saf. 2024. PMID: 39292423 - Evaluation of potential drug-drug interactions with medical cannabis.
Ho JJY, Goh C, Leong CSA, Ng KY, Bakhtiar A. Ho JJY, et al. Clin Transl Sci. 2024 May;17(5):e13812. doi: 10.1111/cts.13812. Clin Transl Sci. 2024. PMID: 38720531 Free PMC article. - CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions.
Qian L, Beers JL, Jackson KD, Zhou Z. Qian L, et al. Pharmaceutics. 2024 Apr 1;16(4):484. doi: 10.3390/pharmaceutics16040484. Pharmaceutics. 2024. PMID: 38675145 Free PMC article. Review. - Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats.
Berthold EC, Kamble SH, Kanumuri SRR, Kuntz MA, Senetra AS, Chiang YH, Mukhopadhyay S, McCurdy CR, Sharma A. Berthold EC, et al. Pharmaceutics. 2024 Feb 24;16(3):318. doi: 10.3390/pharmaceutics16030318. Pharmaceutics. 2024. PMID: 38543213 Free PMC article. - Human Data on Pharmacokinetic Interactions of Cannabinoids: A Narrative Review.
Maldonado C, Peyraube R, Fagiolino P, Oricchio F, Cuñetti L, Vázquez M. Maldonado C, et al. Curr Pharm Des. 2024;30(4):241-254. doi: 10.2174/0113816128288510240113170116. Curr Pharm Des. 2024. PMID: 38288797 Review.
References
REFERENCES
- Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Therap Adv Psychopharmacol. 2012;2(6):241-254.
- Greenwich Biosciences I. Epidiolex (cannabidiol) [prescribing information]. Carlsbad, CA; 2018.
- Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89(5-6):165-170.
- Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88(15-16):730-736.
- Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol. 1993;45(6):1323-1331.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical